Drug intelligence / Profile preview

SBX-2000

Development stage: Preclinical
Lead developer: Stramsen Biotech
Modality: Small Molecules

Overview

SBX-2000 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment and management of various cardiovascular diseases. It is part of the company's proprietary pipeline of therapeutics derived from a database of over 8,000 medicinal plants. While the specific botanical ingredients and molecular targets have not been publicly disclosed, the drug is characterized as a natural herbal medicine that is reportedly already in use in several countries outside the United States. Stramsen Biotech identified SBX-2000 as a lead candidate for clinical development in June 2022, positioning it as a safe and effective plant-derived alternative for cardiovascular health.

Beyond the preview

Go deeper on SBX-2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBX-2000.

Explore the full profile